Lineage Cell Therapeutics Inc

NYSE American: LCTX    
Share price (5/3/24): $1.05    
Market cap (5/3/24): $198 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.04(B)
from 10-K 7 pages Amendment to Stock Option Agreements
12/34/56
EX-10.04(A)
from 10-K 10 pages Re: Separation, Release and Consulting Agreement Dear Gary: This Separation, Release and Consulting Agreement (This “Agreement”) Summarizes the Terms and Conditions of the Separation, Release and Consulting Agreement That Lineage Cell Therapeutics, Inc. (“Lineage”) Is Offering You in Connection With Your Employment Termination. 1. Employment Termination and Final Accrued Payments
12/34/56
EX-10.1
from 8-K 11 pages Stock Purchase Agreement
12/34/56
EX-10.21
from 10-K 14 pages In the Court of Chancery of the State of Delaware
12/34/56
EX-10.07
from 10-K 14 pages Employment Agreement
12/34/56
EX-10.5
from 10-Q 2 pages Executive Performance Incentive Bonus Plan Adopted on September 20, 2022
12/34/56
EX-10.4
from 10-Q 11 pages Amended and Restated Employment Agreement
12/34/56
EX-10.3
from 10-Q 11 pages Amended and Restated Employment Agreement
12/34/56
EX-10.2
from 10-Q 11 pages Amended and Restated Employment Agreement
12/34/56
EX-10.1
from 10-Q 13 pages Form of Indemnification Agreement
12/34/56
EX-10.1
from 8-K 6 pages July 5, 2022 Kevin L. Cook C/O Lineage Cell Therapeutics, Inc. 2173 Salk Avenue, Suite 200 Carlsbad, Ca 92008 Re: Separation Agreement 1. Employment Resignation
12/34/56
EX-10.2
from 8-K 52 pages Share Purchase and Transfer Agreement
12/34/56
EX-10.1
from 8-K 52 pages Certain Information Has Been Omitted From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. in This Exhibit, “[ * ]” Indicates Where Such Information Has Been Omitted. Debt and Note Purchase Agreement
12/34/56
EX-10.13
from 10-K 75 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Collaboration and License Agreement Between Lineage Cell Therapeutics, Inc. and Cell Cure Neurosciences Ltd. and Genentech, Inc. and F. Hoffmann-La Roche Ltd as of December 17, 2021
12/34/56
EX-10.4D
from 10-K 6 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10.4C
from 10-K 9 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Side Letter to Second Amended and Restated License Agreement
12/34/56
EX-10.4B
from 10-K 4 pages Second Amendment to Second Amended and Restated License Agreement
12/34/56
EX-10.2
from 10-Q 9 pages Employment Agreement
12/34/56
EX-10.1
from 10-Q 2 pages First Amendment to Consulting Agreement
12/34/56
EX-10.1
from 8-K 20 pages Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan Adopted by the Board of Directors: July 21, 2021 Approved by the Shareholders: September 13, 2021
12/34/56